share_log

Oramed Pharmaceuticals Analyst Ratings

Benzinga Analyst Ratings ·  Jan 17, 2023 19:16
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/17/2023 HC Wainwright & Co. Downgrades Buy → Neutral
01/12/2023 Canaccord Genuity Downgrades Buy → Hold
05/16/2022 1233.33% Aegis Capital $35 → $30 Maintains Buy
02/18/2022 788.89% Cantor Fitzgerald → $20 Initiates Coverage On → Overweight
11/30/2021 1322.22% HC Wainwright & Co. $17 → $32 Maintains Buy
11/29/2021 1322.22% HC Wainwright & Co. $17 → $32 Maintains Buy
11/02/2021 1455.56% Aegis Capital $20 → $35 Maintains Buy
07/29/2021 1233.33% Canaccord Genuity $27 → $30 Maintains Buy
06/08/2021 788.89% Aegis Capital $12 → $20 Maintains Buy
04/20/2021 1100% Canaccord Genuity → $27 Initiates Coverage On → Buy
02/09/2021 922.22% National Securities Corporation → $23 Initiates Coverage On → Buy
01/27/2021 433.33% Aegis Capital $6 → $12 Maintains Buy
07/13/2020 655.56% HC Wainwright & Co. $16 → $17 Reiterates → Buy
06/22/2020 611.11% HC Wainwright & Co. $20 → $16 Maintains Buy
09/11/2019 211.11% Ladenburg Thalmann → $7 Initiates Coverage On → Buy

What is the target price for Oramed Pharmaceuticals (ORMP)?

The latest price target for Oramed Pharmaceuticals (NASDAQ: ORMP) was reported by HC Wainwright & Co. on January 17, 2023. The analyst firm set a price target for $0.00 expecting ORMP to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?

The latest analyst rating for Oramed Pharmaceuticals (NASDAQ: ORMP) was provided by HC Wainwright & Co., and Oramed Pharmaceuticals downgraded their neutral rating.

When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.

Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?

While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a downgraded with a price target of $0.00 to $0.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.25, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment